Journal article
Long-term MRI-guided combined anti-TNF-α and thiopurine therapy for crohn's perianal fistulas
P Tozer, SC Ng, MR Siddiqui, S Plamondon, D Burling, A Gupta, A Swatton, S Tripoli, CJ Vaizey, MA Kamm, R Phillips, A Hart
Inflammatory Bowel Diseases | OXFORD UNIV PRESS INC | Published : 2012
DOI: 10.1002/ibd.21940
Abstract
Background: Anti-tumor necrosis factor (TNF) therapy heals many Crohn's disease (CD) anal fistulas clinically but the rate, extent, and durability of deep tissue healing and factors influencing long-term outcome are unknown. Methods: Consecutive patients with CD-related perianal (anal, rectovaginal, anolabial) fistulas treated with infliximab or adalimumab were monitored prospectively both clinically and radiologically using magnetic resonance imaging (MRI). Results: Forty-one consecutive patients with CD-related perianal fistulas were treated with infliximab (n = 32) or adalimumab (n = 9; following infliximab failure) in combination with a thiopurine (unless intolerant). Fifty-eight percent..
View full abstractGrants
Funding Acknowledgements
The charities Core and the Ileostomy Association provided funding that supported the preparation of the article. Study partly funded by an unrestricted educational grant from Schering-Plough UK. Schering-Plough UK had no knowledge of the nature, content, or results of the study.Dr. Hart has served as a consultant/speaker for MSD, Shire and Abbott, and has received research/educational grants from Abbott. Michael Kamm has acted as consultant to, speaker for, or received research support from, Abbott, Centocor, Schering-Plough, and UCB.